

Matthew P Goetz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4494283/publications.pdf>

Version: 2024-02-01

167
papers

13,401
citations

43973

48
h-index

24179

110
g-index

174
all docs

174
docs citations

174
times ranked

14847
citing authors

#	ARTICLE	IF	CITATIONS
1	Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 111-121.	13.9	1,558
2	MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 3638-3646.	0.8	1,099
3	Pharmacogenetics of Tamoxifen Biotransformation Is Associated With Clinical Outcomes of Efficacy and Hot Flashes. <i>Journal of Clinical Oncology</i> , 2005, 23, 9312-9318.	0.8	726
4	Percutaneous Image-Guided Radiofrequency Ablation of Painful Metastases Involving Bone: A Multicenter Study. <i>Journal of Clinical Oncology</i> , 2004, 22, 300-306.	0.8	573
5	The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. <i>Breast Cancer Research and Treatment</i> , 2007, 101, 113-121.	1.1	520
6	Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 1429.	3.8	468
7	Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 122-137.	13.9	448
8	MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. <i>Npj Breast Cancer</i> , 2019, 5, 5.	2.3	352
9	Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 2395-2405.	13.9	349
10	Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients With Advanced Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 1078-1087.	0.8	328
11	NCCN Guidelines Insights: Breast Cancer, Version 1.2017. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 433-451.	2.3	317
12	Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2015, 33, 2695-2704.	0.8	279
13	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for <i>CYP2D6</i> and Tamoxifen Therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 770-777.	2.3	244
14	NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 4055-4065.	3.2	243
15	The Tamoxifen Metabolite, Endoxifen, Is a Potent Antiestrogen that Targets Estrogen Receptor β for Degradation in Breast Cancer Cells. <i>Cancer Research</i> , 2009, 69, 1722-1727.	0.4	200
16	Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies. <i>Cancers</i> , 2020, 12, 2392.	1.7	171
17	Neratinib Efficacy and Circulating Tumor DNA Detection of <i>HER2</i> Mutations in <i>HER2</i> Nonamplified Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 5687-5695.	3.2	170
18	Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. <i>Lancet Oncology</i> , The, 2021, 22, 212-222.	5.1	169

#	ARTICLE	IF	CITATIONS
19	Tamoxifen Pharmacogenomics: The Role of CYP2D6 as a Predictor of Drug Response. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 83, 160-166.	2.3	158
20	Breast Cancer, Version 3.2018. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 118-126.	2.3	158
21	A Two-Gene Expression Ratio of Homeobox 13 and Interleukin-17B Receptor for Prediction of Recurrence and Survival in Women Receiving Adjuvant Tamoxifen. <i>Clinical Cancer Research</i> , 2006, 12, 2080-2087.	3.2	151
22	Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. <i>Lancet Oncology</i> , The, 2022, 23, 149-160.	5.1	148
23	The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immunology biomarkers in breast cancer clinical trials and daily practice. <i>Journal of Pathology</i> , 2020, 250, 667-684.	2.1	142
24	Breast Cancer, Version 1.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 1475-1485.	2.3	134
25	DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine. <i>Journal of Clinical Investigation</i> , 2018, 128, 2376-2388.	3.9	134
26	Coprescription of Tamoxifen and Medications That Inhibit CYP2D6. <i>Journal of Clinical Oncology</i> , 2010, 28, 2768-2776.	0.8	122
27	CDK4/6-dependent activation of DUB3 regulates cancer metastasis through SNAIL1. <i>Nature Communications</i> , 2017, 8, 13923.	5.8	119
28	A comprehensive analysis of breast cancer microbiota and host gene expression. <i>PLoS ONE</i> , 2017, 12, e0188873.	1.1	111
29	CYP2D6 Metabolism and Patient Outcome in the Austrian Breast and Colorectal Cancer Study Group Trial (ABCSCG) 8. <i>Clinical Cancer Research</i> , 2013, 19, 500-507.	3.2	107
30	A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 1095-1102.	3.2	98
31	Clinical implementation of pharmacogenomics: overcoming genetic exceptionalism. <i>Lancet Oncology</i> , The, 2010, 11, 507-509.	5.1	97
32	Tamoxifen Use in Postmenopausal Breast Cancer: CYP2D6 Matters. <i>Journal of Clinical Oncology</i> , 2013, 31, 176-180.	0.8	97
33	Carnitine Palmitoyltransferase 1A Has a Lysine Succinyltransferase Activity. <i>Cell Reports</i> , 2018, 22, 1365-1373.	2.9	85
34	Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 89-99.	1.1	74
35	A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 6823-6832.	3.2	66
36	Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 944-951.	1.9	64

#	ARTICLE	IF	CITATIONS
37	Evaluation of Germline Genetic Testing Criteria in a Hospital-Based Series of Women With Breast Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 1409-1418.	0.8	64
38	Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3. <i>Oncologist</i> , 2021, 26, e53-e65.	1.9	64
39	Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial. <i>Journal of the National Cancer Institute</i> , 2021, 113, 390-399.	3.0	62
40	Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention. <i>Cancer Discovery</i> , 2013, 3, 812-825.	7.7	61
41	TBCRC 008: Early Change in ^{18}F -FDG Uptake on PET Predicts Response to Preoperative Systemic Therapy in Human Epidermal Growth Factor Receptor 2-Negative Primary Operable Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2015, 56, 31-37.	2.8	61
42	Tumor Sequencing and Patient-Derived Xenografts in the Neoadjuvant Treatment of Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	61
43	ATR Inhibition Is a Promising Radiosensitizing Strategy for Triple-Negative Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 2462-2472.	1.9	59
44	Estrogen receptor-beta sensitizes breast cancer cells to the anti-estrogenic actions of endoxifen. <i>Breast Cancer Research</i> , 2011, 13, R27.	2.2	58
45	First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 3391-3400.	0.8	58
46	NOTCH3 expression is linked to breast cancer seeding and distant metastasis. <i>Breast Cancer Research</i> , 2018, 20, 105.	2.2	58
47	Regulation of sister chromatid cohesion by nuclear PD-L1. <i>Cell Research</i> , 2020, 30, 590-601.	5.7	58
48	Metaplastic breast cancer has a poor response to neoadjuvant systemic therapy. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 709-716.	1.1	54
49	ER $^{\pm}$ 21: characterization, prognosis, and evaluation of treatment strategies in ER $^{\pm}$ -positive and -negative breast cancer. <i>BMC Cancer</i> , 2014, 14, 749.	1.1	53
50	Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study. <i>Breast Cancer Research</i> , 2017, 19, 130.	2.2	53
51	Predicting Nodal Positivity in Women 70 Years of Age and Older with Hormone Receptor-Positive Breast Cancer to Aid Incorporation of a Society of Surgical Oncology Choosing Wisely Guideline into Clinical Practice. <i>Annals of Surgical Oncology</i> , 2017, 24, 2881-2888.	0.7	52
52	Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (alliance). <i>Annals of Oncology</i> , 2016, 27, 339-344.	0.6	51
53	Evaluation of CYP2D6 and Efficacy of Tamoxifen and Raloxifene in Women Treated for Breast Cancer Chemoprevention: Results from the NSABP P1 and P2 Clinical Trials. <i>Clinical Cancer Research</i> , 2011, 17, 6944-6951.	3.2	49
54	Discovery of a Glucocorticoid Receptor (GR) Activity Signature Using Selective GR Antagonism in ER-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 3433-3446.	3.2	49

#	ARTICLE	IF	CITATIONS
55	Folate receptor alpha expression associates with improved disease-free survival in triple negative breast cancer patients. <i>Npj Breast Cancer</i> , 2020, 6, 4.	2.3	49
56	FOXA1 overexpression suppresses interferon signaling and immune response in cancer. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	48
57	Landscape of Neoadjuvant Therapy for Breast Cancer. <i>Annals of Surgical Oncology</i> , 2015, 22, 1408-1415.	0.7	47
58	Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor Therapy. <i>Cancer Research</i> , 2016, 76, 7012-7023.	0.4	47
59	ER β -mediated induction of cystatins results in suppression of TGF β signaling and inhibition of triple-negative breast cancer metastasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E9580-E9589.	3.3	47
60	Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52. <i>Breast Cancer Research and Treatment</i> , 2006, 98, 217-222.	1.1	46
61	Tyrosine Phosphorylation of Mitochondrial Creatine Kinase 1 Enhances a Druggable Tumor Energy Shuttle Pathway. <i>Cell Metabolism</i> , 2018, 28, 833-847.e8.	7.2	46
62	Phase I and Pharmacokinetic Study of Two Different Schedules of Oxaliplatin, Irinotecan, Fluorouracil, and Leucovorin in Patients With Solid Tumors. <i>Journal of Clinical Oncology</i> , 2003, 21, 3761-3769.	0.8	42
63	Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy. <i>Npj Breast Cancer</i> , 2018, 4, 41.	2.3	41
64	<i>SULT1A1</i>,<i>CYP2C19</i> and disease-free survival in early breast cancer patients receiving tamoxifen. <i>Pharmacogenomics</i> , 2011, 12, 1535-1543.	0.6	39
65	Pharmacokinetics of endoxifen and tamoxifen in female mice: implications for comparative in vivo activity studies. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 1271-1278.	1.1	39
66	A phase I study of cilengitide and paclitaxel in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 1221-1227.	1.1	39
67	Endoxifen's Molecular Mechanisms of Action Are Concentration Dependent and Different than That of Other Anti-Estrogens. <i>PLoS ONE</i> , 2013, 8, e54613.	1.1	38
68	Estrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozole. <i>Steroids</i> , 2015, 99, 32-38.	0.8	38
69	Mapping molecular subtype specific alterations in breast cancer brain metastases identifies clinically relevant vulnerabilities. <i>Nature Communications</i> , 2022, 13, 514.	5.8	38
70	Loss of Heterozygosity at the CYP2D6 Locus in Breast Cancer: Implications for Germline Pharmacogenetic Studies. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	37
71	Phase I Study of Panobinostat (LBH589) and Letrozole in Postmenopausal Metastatic Breast Cancer Patients. <i>Clinical Breast Cancer</i> , 2016, 16, 82-86.	1.1	37
72	The lncRNA MIR2052HG regulates ER α levels and aromatase inhibitor resistance through LMTK3 by recruiting EGR1. <i>Breast Cancer Research</i> , 2019, 21, 47.	2.2	36

#	ARTICLE	IF	CITATIONS
73	Has the Time Come to Stop Surgical Staging of the Axilla for All Women Age 70 Years or Older with Hormone Receptor-Positive Breast Cancer?. <i>Annals of Surgical Oncology</i> , 2017, 24, 614-617.	0.7	35
74	ER β inhibits cyclin dependent kinases 1 and 7 in triple negative breast cancer. <i>Oncotarget</i> , 2017, 8, 96506-96521.	0.8	35
75	Aurora-A kinase oncogenic signaling mediates TGF- β -induced triple-negative breast cancer plasticity and chemoresistance. <i>Oncogene</i> , 2021, 40, 2509-2523.	2.6	34
76	Regional lymphadenopathy following COVID-19 vaccination: Literature review and considerations for patient management in breast cancer care. <i>European Journal of Cancer</i> , 2021, 159, 38-51.	1.3	34
77	Clonal expansion of antitumor T cells in breast cancer correlates with response to neoadjuvant chemotherapy. <i>International Journal of Oncology</i> , 2016, 49, 471-478.	1.4	32
78	North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic β -based dosing of irinotecan, oxaliplatin, and capecitabine as first β -line therapy for patients with advanced small bowel adenocarcinoma. <i>Cancer</i> , 2017, 123, 3494-3501.	2.0	32
79	Characteristics and Spatially Defined Immune (micro)landscapes of Early-stage PD-L1 β -positive Triple-negative Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5628-5637.	3.2	32
80	Pregnancy-associated plasma protein-A expression in human breast cancer. <i>Growth Hormone and IGF Research</i> , 2014, 24, 264-267.	0.5	31
81	Optimized immunohistochemical detection of estrogen receptor beta using two validated monoclonal antibodies confirms its expression in normal and malignant breast tissues. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 241-249.	1.1	31
82	MRI Radiomics for Assessment of Molecular Subtype, Pathological Complete Response, and Residual Cancer Burden in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy. <i>Academic Radiology</i> , 2022, 29, S145-S154.	1.3	31
83	Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups. <i>Npj Breast Cancer</i> , 2021, 7, 80.	2.3	31
84	The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1258-1267.	3.2	31
85	Health β -Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR +, HER2 β Advanced Breast Cancer. <i>Oncologist</i> , 2020, 25, e1346-e1354.	1.9	28
86	Implementation of preemptive DNA sequence β -based pharmacogenomics testing across a large academic medical center: The Mayo-Baylor RIGHT 10K Study. <i>Genetics in Medicine</i> , 2022, 24, 1062-1072.	1.1	28
87	Estrogen, SNP-Dependent Chemokine Expression and Selective Estrogen Receptor Modulator Regulation. <i>Molecular Endocrinology</i> , 2016, 30, 382-398.	3.7	27
88	Exome sequencing reveals frequent deleterious germline variants in cancer susceptibility genes in women with invasive breast cancer undergoing neoadjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2015, 153, 435-443.	1.1	26
89	The emerging role of CDK4/6i in HER2-positive breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591988766.	1.4	25
90	Treatment Exposure and Discontinuation in the PALbociclib CoLLaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor β -Positive/Human Epidermal Growth Factor Receptor 2 β -Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03). <i>Journal of Clinical Oncology</i> , 2022, 40, 449-458.	0.8	25

#	ARTICLE	IF	CITATIONS
91	Cytochrome P450 2D6 and Homeobox 13/Interleukin-17B Receptor: Combining Inherited and Tumor Gene Markers for Prediction of Tamoxifen Resistance. <i>Clinical Cancer Research</i> , 2008, 14, 5864-5868.	3.2	23
92	Accuracy of an Artificial Intelligence System for Cancer Clinical Trial Eligibility Screening: Retrospective Pilot Study. <i>JMIR Medical Informatics</i> , 2021, 9, e27767.	1.3	23
93	Breast Medical Oncologists' Use of Standard Prognostic Factors to Predict a 21-gene Recurrence Score. <i>Oncologist</i> , 2011, 16, 1359-1366.	1.9	21
94	UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine. <i>Investigational New Drugs</i> , 2013, 31, 1559-1567.	1.2	21
95	Phase I trial to evaluate the addition of alisertib to fulvestrant in women with endocrine-resistant, ER+ metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 639-647.	1.1	21
96	Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial. <i>Breast Cancer Research</i> , 2021, 23, 87.	2.2	21
97	A Multidisciplinary Approach to the Management of Breast Cancer, Part 2: Therapeutic Considerations. <i>Mayo Clinic Proceedings</i> , 2007, 82, 1131-1140.	1.4	20
98	Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials. <i>Breast Cancer Research and Treatment</i> , 2021, 186, 417-428.	1.1	20
99	Activation of PI3K/Akt/mTOR signaling in the tumor stroma drives endocrine therapy-dependent breast tumor regression. <i>Oncotarget</i> , 2015, 6, 22081-22097.	0.8	20
100	Once-Daily Radiation Therapy for Inflammatory Breast Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 997-1003.	0.4	19
101	A clinical calculator to predict disease outcomes in women with triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 557-566.	1.1	19
102	Use of 21-gene recurrence score assay to individualize adjuvant chemotherapy recommendations in ER+/HER2- node positive breast cancer: A National Cancer Database study. <i>Npj Breast Cancer</i> , 2017, 3, 41.	2.3	18
103	Breast cancer chemoprevention pharmacogenomics: Deep sequencing and functional genomics of the ZNF423 and CTSO genes. <i>Npj Breast Cancer</i> , 2017, 3, 30.	2.3	18
104	Comparative Uterotrophic Effects of Endoxifen and Tamoxifen in Ovariectomized Sprague-Dawley Rats. <i>Toxicologic Pathology</i> , 2014, 42, 1188-1196.	0.9	17
105	SLCO1B1 polymorphisms and plasma estrone conjugates in postmenopausal women with ER+ breast cancer: genome-wide association studies of the estrone pathway. <i>Breast Cancer Research and Treatment</i> , 2017, 164, 189-199.	1.1	17
106	The novel function of tumor protein D54 in regulating pyruvate dehydrogenase and metformin cytotoxicity in breast cancer. <i>Cancer & Metabolism</i> , 2019, 7, 1.	2.4	17
107	Tamoxifen Metabolism and Breast Cancer Recurrence: A Question Unanswered by CYPTAM. <i>Journal of Clinical Oncology</i> , 2019, 37, 1982-1983.	0.8	17
108	Anastrozole has an Association between Degree of Estrogen Suppression and Outcomes in Early Breast Cancer and is a Ligand for Estrogen Receptor β . <i>Clinical Cancer Research</i> , 2020, 26, 2986-2996.	3.2	17

#	ARTICLE	IF	CITATIONS
109	Clinical performance pilot using cognitive computing for clinical trial matching at Mayo Clinic.. Journal of Clinical Oncology, 2018, 36, e18598-e18598.	0.8	17
110	Inhibition of ATM Induces Hypersensitivity to Proton Irradiation by Upregulating Toxic End Joining. Cancer Research, 2021, 81, 3333-3346.	0.4	16
111	Quantitative Analysis of Tyrosine Phosphorylation from FFPE Tissues Reveals Patient-Specific Signaling Networks. Cancer Research, 2021, 81, 3930-3941.	0.4	16
112	Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action. JCI Insight, 2020, 5, .	2.3	16
113	Clinical pharmacogenomic testing and reporting: A technical standard of the American College of Medical Genetics and Genomics (ACMG). Genetics in Medicine, 2022, 24, 759-768.	1.1	16
114	Comparison of ^{99m} Tc-Sestamibi Molecular Breast Imaging and Breast MRI in Patients With Invasive Breast Cancer Receiving Neoadjuvant Chemotherapy. American Journal of Roentgenology, 2019, 213, 932-943.	1.0	15
115	Baseline estrogen levels in postmenopausal women participating in the MAP.3 breast cancer chemoprevention trial. Menopause, 2020, 27, 693-700.	0.8	15
116	Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2 ⁺ advanced breast cancer: MONARCH 2 & 3 trials. Cancer Science, 2021, 112, 2381-2392.	1.7	15
117	CYP2D6 and Tamoxifen: Awaiting the Denouement. Journal of Clinical Oncology, 2011, 29, 4589-4590.	0.8	14
118	CYP2D6 Genotype and Tamoxifen: Considerations for Proper Nonprospective Studies. Clinical Pharmacology and Therapeutics, 2014, 96, 141-144.	2.3	14
119	HGT-ID: an efficient and sensitive workflow to detect human-viral insertion sites using next-generation sequencing data. BMC Bioinformatics, 2018, 19, 271.	1.2	14
120	Endoxifen, an Estrogen Receptor Targeted Therapy: From Bench to Bedside. Endocrinology, 2021, 162, .	1.4	14
121	Case-Based Review and Clinical Guidance on the Use of Genomic Assays for Early-Stage Breast Cancer: Breast Cancer Therapy Expert Group (BCTEG). Clinical Breast Cancer, 2020, 20, 183-193.	1.1	13
122	Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG). Breast Cancer Research and Treatment, 2018, 169, 1-7.	1.1	12
123	Evaluation of CYP2D6 enzyme activity using a ¹³ C-dextromethorphan breath test in women receiving adjuvant tamoxifen. Pharmacogenetics and Genomics, 2015, 25, 157-163.	0.7	11
124	Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer. Breast Cancer Research, 2020, 22, 51.	2.2	11
125	Spontaneous murine tumors in the development of patient-derived xenografts: a potential pitfall. Oncotarget, 2019, 10, 3924-3930.	0.8	11
126	Anastrozole Aromatase Inhibitor Plasma Drug Concentration Genome-Wide Association Study: Functional Epistatic Interaction Between <i>SLC38A7</i> and <i>ALPPL2</i> . Clinical Pharmacology and Therapeutics, 2019, 106, 219-227.	2.3	10

#	ARTICLE	IF	CITATIONS
127	Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. <i>Breast Cancer</i> , 2022, 29, 174-184.	1.3	10
128	Factors Influencing Use of Hormone Therapy for Ductal Carcinoma In Situ: A National Cancer Database Study. <i>Annals of Surgical Oncology</i> , 2017, 24, 2989-2998.	0.7	9
129	Salicylates enhance CRM1 inhibitor antitumor activity by induction of S-phase arrest and impairment of DNA-damage repair. <i>Blood</i> , 2021, 137, 513-523.	0.6	9
130	Estrogen receptor beta repurposes EZH2 to suppress oncogenic NF κ B/p65 signaling in triple negative breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 20.	2.3	9
131	Neoadjuvant Chemotherapy and Nodal Response Rates in Luminal Breast Cancer: Effects of Age and Tumor Ki67. <i>Annals of Surgical Oncology</i> , 2022, 29, 5747-5756.	0.7	9
132	The Effects of a Novel Hormonal Breast Cancer Therapy, Endoxifen, on the Mouse Skeleton. <i>PLoS ONE</i> , 2014, 9, e98219.	1.1	8
133	Providing Balance in ASCO Clinical Practice Guidelines: CYP2D6 Genotyping and Tamoxifen Efficacy. <i>Journal of Clinical Oncology</i> , 2016, 34, 3944-3945.	0.8	8
134	Pharmacogenetic dosing by UGT1A1 genotype as first-line therapy for advanced small-bowel adenocarcinoma: A North Central Cancer Treatment Group (NCCTG) trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 314-314.	0.8	8
135	Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 \hat{A} + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer. <i>Future Oncology</i> , 2021, 17, 4665-4676.	1.1	8
136	Patient-Derived Xenograft Engraftment and Breast Cancer Outcomes in a Prospective Neoadjuvant Study (BEAUTY). <i>Clinical Cancer Research</i> , 2021, 27, 4696-4699.	3.2	7
137	The association of early toxicity and outcomes for patients treated with abemaciclib. <i>Journal of Clinical Oncology</i> , 2018, 36, 1053-1053.	0.8	7
138	Phase II Trial of Oxaliplatin/Irinotecan/5-Fluorouracil/Leucovorin for Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2007, 6, 516-521.	1.0	6
139	Skeletal and Uterotrophic Effects of Endoxifen in Female Rats. <i>Endocrinology</i> , 2017, 158, 3354-3368.	1.4	6
140	Phase 1 study of Z-Endoxifen in patients with advanced gynecologic, desmoid, and hormone receptor-positive solid tumors. <i>Oncotarget</i> , 2021, 12, 268-277.	0.8	6
141	Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study. <i>Frontiers in Oncology</i> , 2021, 11, 810023.	1.3	6
142	Tamoxifen, endoxifen, and CYP2D6: the rules for evaluating a predictive factor. <i>Oncology</i> , 2009, 23, 1233-4, 1236.	0.4	6
143	Gene-Expression \hat{A} -Based Predictors for Breast Cancer. <i>New England Journal of Medicine</i> , 2007, 356, 752-753.	13.9	5
144	A phase I study of the farnesyltransferase inhibitor Tipifarnib in combination with the epidermal growth factor tyrosine kinase inhibitor Erlotinib in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2019, 37, 307-314.	1.2	5

#	ARTICLE	IF	CITATIONS
145	Interaction Between SNP Genotype and Efficacy of Anastrozole and Exemestane in Early-Stage Breast Cancer. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 1038-1049.	2.3	5
146	Establishment and characterization of immortalized human breast cancer cell lines from breast cancer patient-derived xenografts (PDX). <i>Npj Breast Cancer</i> , 2021, 7, 79.	2.3	5
147	Gemcitabine and Irinotecan as First-Line Therapy for Carcinoma of Unknown Primary: Results of a Multicenter Phase II Trial. <i>PLoS ONE</i> , 2012, 7, e39285.	1.1	5
148	Developments in combination chemotherapy for colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2004, 4, 627-637.	1.1	4
149	Re: Concordance Between CYP2D6 Genotypes Obtained From Tumor-Derived and Germline DNA. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	4
150	Concordance between predicted HLA type using next generation sequencing data generated for non-HLA purposes and clinical HLA type. <i>Human Immunology</i> , 2020, 81, 423-429.	1.2	4
151	Decreasing the Use of Sentinel Lymph Node Surgery in Women Older than 70 Years with Hormone Receptor-Positive Breast Cancer and the Impact on Adjuvant Radiation and Hormonal Therapy. <i>Annals of Surgical Oncology</i> , 2021, 28, 8766-8774.	0.7	4
152	Anastrozole Regulates Fatty Acid Synthase in Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 206-216.	1.9	4
153	Genetic polymorphisms of CYP2D6*10 and CYP2C19*2, *3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen. <i>Cancer</i> , 2010, 116, 1007-1007.	2.0	3
154	Reply to A.-S. Dieudonné et al and J.M. Rae et al. <i>Journal of Clinical Oncology</i> , 2013, 31, 2755-2756.	0.8	3
155	Window-of-Opportunity Trials in the Preoperative Setting: Insights Into Drug Development for Estrogen Receptor-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 1970-1972.	0.8	3
156	Early discontinuation of tamoxifen. <i>Cancer</i> , 2007, 110, 2595-2595.	2.0	2
157	A Transcriptionally Definable Subgroup of Triple-Negative Breast and Ovarian Cancer Samples Shows Sensitivity to HSP90 Inhibition. <i>Clinical Cancer Research</i> , 2020, 26, 159-170.	3.2	2
158	Development and Characterization of Novel Endoxifen-Resistant Breast Cancer Cell Lines Highlight Numerous Differences from Tamoxifen-Resistant Models. <i>Molecular Cancer Research</i> , 2021, 19, 1026-1039.	1.5	2
159	Multidisciplinary Management of Breast Cancer With Extensive Regional Nodal Involvement. <i>Journal of Clinical Oncology</i> , 2020, 38, 2290-2298.	0.8	2
160	Aromatase inhibitors and tamoxifen: where do we go from here?. <i>Nature Clinical Practice Oncology</i> , 2007, 4, 626-627.	4.3	1
161	6. Clinical Use of Selective Estrogen Receptor Modulators and Aromatase Inhibitors in Prevention and Adjuvant Treatment of Breast Cancer. <i>Translational Endocrinology & Metabolism</i> , 2012, , 139-167.	0.2	1
162	Using Size and Grade to Identify Women Aged 70 Years with Endocrine-Responsive Breast Cancer at Low Risk of Nodal Positivity. <i>Annals of Surgical Oncology</i> , 2017, 24, 557-558.	0.7	1

#	ARTICLE	IF	CITATIONS
163	Update on CYP2D6 and Tamoxifen. <i>Clinical Advances in Hematology and Oncology</i> , 2013, 11, 178-80.	0.3	1
164	Reply to S.L. Gomez et al. <i>Journal of Clinical Oncology</i> , 2010, 28, e158-e158.	0.8	0
165	ASO Visual Abstract: Decreasing the Use of Sentinel Lymph Node Surgery in Women Over 70 Years Old with Hormone Receptor Positive Breast Cancer and the Impact on Adjuvant Radiation and Hormonal Therapy. <i>Annals of Surgical Oncology</i> , 2021, 28, 620-621.	0.7	0
166	Pharmacogenomics of Tamoxifen. , 2011, , 77-89.		0
167	Population Pharmacokinetics of Endoxifen in Patients with Advanced Solid Tumors. <i>Journal of Clinical Pharmacology</i> , 2022, , .	1.0	0